A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810) ADMINISTERED INTRALESIONALLY FOR PATIENTS WITH RECURRENT CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC)

Brief description of study

The main purpose of this study is to determine the safet and tolerability of cemiplimab. Cemiplimab-rwic is only approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic cutaneous squamous celi carcinoma (CSCC) or locaiiy advanced CSCC who are not candidates for curative surgery or curative radiation • Side effects that may be experienced by peopie taking cemiplimab • How cemiplimab works in the body • How much cemiplimab is present in your blood • To see effect of cemiplimab on your tumor

Clinical Study Identifier: s19-01357

ClinicalTrials.gov Identifier: NCT03889912

Principal Investigator: John A. Carucci.

Other Investigators: Mary L. Stevenson, Nayoung Lee.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies